GT200600316A - Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. - Google Patents

Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.

Info

Publication number
GT200600316A
GT200600316A GT200600316A GT200600316A GT200600316A GT 200600316 A GT200600316 A GT 200600316A GT 200600316 A GT200600316 A GT 200600316A GT 200600316 A GT200600316 A GT 200600316A GT 200600316 A GT200600316 A GT 200600316A
Authority
GT
Guatemala
Prior art keywords
ilo
methyl
iloamino
pirimidina
trifluorometilo
Prior art date
Application number
GT200600316A
Other languages
English (en)
Inventor
Paul W Manley
Wen-Chung Shieh
Paul Allen Sutton
Piotr H Karpinski
Raeann Wu
Stephanie Monnier
Joerg Brozio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37398525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200600316(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200600316A publication Critical patent/GT200600316A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

LA PRESENTE INVENCIÓN SE RELACIONA CON LAS SALES DE 4-METILO-N-(3-(4-METILO-IMIDAZOL-1-ILO)-5-TRIFLUOROMETILO-FENILO)-3-(4-PIRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO)- BENZAMIDA, ASI COMO CON LOS METODOS PARA SU PREPARACION, LAS COMPOSICIONES FARMACEUTICAS QUE LO COMPRENDEN Y LOS METODOS DE TRATAMIENTO UTILIZANDO DICHA INVENCION EN LA INHIBICION DE LA ACTIVIDAD DE LA PROTEINA QUINASA.
GT200600316A 2005-07-20 2006-07-14 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. GT200600316A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70140605P 2005-07-20 2005-07-20
US71621305P 2005-09-12 2005-09-12

Publications (1)

Publication Number Publication Date
GT200600316A true GT200600316A (es) 2007-04-02

Family

ID=37398525

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600316A GT200600316A (es) 2005-07-20 2006-07-14 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.

Country Status (34)

Country Link
US (4) US8163904B2 (es)
EP (2) EP1910336B1 (es)
JP (1) JP5129132B2 (es)
KR (3) KR101755137B1 (es)
CN (1) CN102267981A (es)
AR (1) AR057467A1 (es)
AT (1) ATE514689T1 (es)
AU (2) AU2006276205B2 (es)
BR (1) BRPI0613605A2 (es)
CA (2) CA2615669C (es)
CY (1) CY1111772T1 (es)
DK (1) DK1910336T3 (es)
EC (1) ECSP088118A (es)
ES (1) ES2634291T3 (es)
GT (1) GT200600316A (es)
HK (1) HK1116778A1 (es)
HR (1) HRP20110639T1 (es)
IL (1) IL187787A (es)
JO (1) JO2757B1 (es)
MA (1) MA29686B1 (es)
MX (1) MX2008000892A (es)
MY (1) MY149889A (es)
NO (1) NO341313B1 (es)
NZ (2) NZ591142A (es)
PE (1) PE20070241A1 (es)
PL (1) PL1910336T3 (es)
PT (1) PT1910336E (es)
RU (4) RU2509767C1 (es)
SG (1) SG170772A1 (es)
SI (1) SI1910336T1 (es)
TN (1) TNSN08028A1 (es)
TW (1) TWI455934B (es)
UY (1) UY29683A1 (es)
WO (1) WO2007015871A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
CA2644841C (en) * 2006-04-07 2013-07-16 Novartis Ag Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
US20100016590A1 (en) 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
PL2262793T3 (pl) 2008-11-05 2013-01-31 Teva Pharma Formy krystaliczne nilotynibu HCL
EP2186514B1 (en) 2008-11-14 2016-06-29 Kinki University Treatment of Malignant Peripheral Nerve Sheath Tumors
EP2403492A1 (en) 2009-03-06 2012-01-11 Novartis AG Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper- and sterile alpha motif-containing kinase (zak)
TW201102068A (en) 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
US20110053968A1 (en) 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
WO2011033307A1 (en) 2009-09-17 2011-03-24 Generics [Uk] Limited Nilotinib dihydrochloride salt
NZ599217A (en) 2009-10-23 2014-05-30 Novartis Ag Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
IN2010KO00035A (es) 2010-01-15 2016-09-02
EP2558098A2 (en) 2010-04-16 2013-02-20 Novartis AG Treatment of endocrine resistant breast cancer
EP2382976A1 (en) 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
US8937082B2 (en) 2010-06-21 2015-01-20 Teva Pharmaceutical Industries Ltd. Nilotinib salts and crystalline forms thereof
WO2012014127A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
CN102453024B (zh) * 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
EP2648519A4 (en) * 2010-11-26 2014-04-30 Hetero Research Foundation NEW POLYMORPH OF NILOTINIB HYDROCHLORIDE
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
CA2853095A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
CN103930094A (zh) 2011-11-14 2014-07-16 诺华股份有限公司 即释4-甲基-3[[4-(3-吡啶基)-2-嘧啶基]氨基]-n-[5-(4-甲基-1h-咪唑-1-基)-3-(三氟甲基)苯基]苯甲酰胺剂型
EP2872142A1 (en) 2012-07-11 2015-05-20 Novartis AG Method of treating gastrointestinal stromal tumors
AU2013332205B2 (en) * 2012-10-15 2017-08-31 Apotex Inc. Solid forms of Nilotinib hydrochloride
WO2014060449A1 (en) * 2012-10-19 2014-04-24 Basf Se Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
NZ714378A (en) 2013-04-24 2020-08-28 Dr Reddys Laboratories Ltd Polymorphic forms of nilotinib hydrochloride
RU2551359C9 (ru) * 2013-11-28 2021-08-20 Общество с ограниченной ответственностью "Мамонт Фарм" Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
US9926296B2 (en) 2014-08-08 2018-03-27 Dr. Reddy's Laboratories Limited Process for the preparation of polymorphic forms of nilotinib hydrochloride
PL3189045T3 (pl) 2014-08-11 2022-04-04 Sun Pharmaceutical Industries Limited Nowe sole nilotynibu i jego polimorfy
EP3271351A1 (en) 2015-03-20 2018-01-24 Cipla Limited Novel polymorphic form x of nilotinib dihydrochloride hydrate
SI3408264T1 (sl) 2016-01-26 2020-07-31 Farma Grs, D.O.O. Nilotinibijev dinitrat (V) in njegove kristalne oblike
WO2017149550A1 (en) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
SI3430004T1 (sl) 2016-03-14 2021-03-31 Pliva Hrvatska D.O.O. Trdne oblike soli nilotiniba
EP3404025B1 (en) 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure nilotinib and its salt
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
CN113321647A (zh) * 2018-06-15 2021-08-31 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
US20210380557A1 (en) * 2018-11-05 2021-12-09 Laurus Labs Limited Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same
EP3914252A4 (en) * 2019-02-18 2022-03-30 Slayback Pharma LLC PHARMACEUTICAL COMPOSITION OF NILOTINIB
CA3168680A1 (en) 2020-01-31 2021-08-05 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
US20230075170A1 (en) 2020-02-15 2023-03-09 Cipla Limited Novel salts of nilotinib and polymorphic forms thereof
EP4142699A1 (en) 2020-04-30 2023-03-08 Nanocopoeia LLC Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN114133378B (zh) * 2020-09-04 2023-08-15 成都苑东生物制药股份有限公司 一种盐酸尼洛替尼共晶及其制备方法
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2081108C1 (ru) * 1991-10-16 1997-06-10 Циба-Гейги АГ Аддитивные соли кислот с основанием и фармацевтическая композиция, обладающая противоопухолевой активностью
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
AU691834B2 (en) 1993-10-01 1998-05-28 Novartis Ag Pharmacologically active pyridine derivatives and processes for the preparation thereof
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
KR20020060998A (ko) * 1999-12-14 2002-07-19 니뽄 신야쿠 가부시키가이샤 복소환 유도체 및 의약
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
PE20051096A1 (es) 2004-02-04 2006-01-23 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida
SA06270147B1 (ar) * 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.

Also Published As

Publication number Publication date
IL187787A (en) 2012-07-31
WO2007015871A1 (en) 2007-02-08
US8163904B2 (en) 2012-04-24
AR057467A1 (es) 2007-12-05
US20120270891A1 (en) 2012-10-25
AU2010241419B2 (en) 2012-03-29
KR101755137B1 (ko) 2017-07-06
JP5129132B2 (ja) 2013-01-23
RU2434864C2 (ru) 2011-11-27
RU2605551C2 (ru) 2016-12-20
MX2008000892A (es) 2008-03-18
KR20080027855A (ko) 2008-03-28
SI1910336T1 (sl) 2011-10-28
PL1910336T3 (pl) 2011-11-30
NO341313B1 (no) 2017-10-09
PT1910336E (pt) 2011-09-05
JP2009502796A (ja) 2009-01-29
BRPI0613605A2 (pt) 2011-01-18
NO20080897L (no) 2008-02-20
TNSN08028A1 (en) 2009-07-14
RU2483065C2 (ru) 2013-05-27
CY1111772T1 (el) 2015-10-07
KR20150100946A (ko) 2015-09-02
NZ591142A (en) 2012-09-28
PE20070241A1 (es) 2007-03-22
MY149889A (en) 2013-10-31
RU2011120363A (ru) 2012-11-27
UY29683A1 (es) 2007-02-28
AU2006276205A1 (en) 2007-02-08
RU2013101749A (ru) 2014-07-27
EP1910336A1 (en) 2008-04-16
AU2006276205B2 (en) 2010-08-19
ECSP088118A (es) 2008-02-20
KR20140047737A (ko) 2014-04-22
US20130137712A1 (en) 2013-05-30
EP2186808B1 (en) 2017-04-19
EP2186808A1 (en) 2010-05-19
AU2010241419A1 (en) 2010-12-02
US20140038994A1 (en) 2014-02-06
IL187787A0 (en) 2008-08-07
EP1910336B1 (en) 2011-06-29
MA29686B1 (fr) 2008-08-01
TW200800950A (en) 2008-01-01
JO2757B1 (en) 2014-03-15
CA2615669A1 (en) 2007-02-08
ATE514689T1 (de) 2011-07-15
ES2634291T3 (es) 2017-09-27
RU2008105827A (ru) 2009-08-27
NZ564182A (en) 2011-03-31
RU2509767C1 (ru) 2014-03-20
US8580806B2 (en) 2013-11-12
DK1910336T3 (da) 2011-10-03
US20080200487A1 (en) 2008-08-21
US8389537B2 (en) 2013-03-05
CA2823946C (en) 2015-12-29
HRP20110639T1 (hr) 2011-10-31
TWI455934B (zh) 2014-10-11
US9163005B2 (en) 2015-10-20
SG170772A1 (en) 2011-05-30
HK1116778A1 (es) 2009-01-02
CA2823946A1 (en) 2007-02-08
CN102267981A (zh) 2011-12-07
CA2615669C (en) 2013-11-12

Similar Documents

Publication Publication Date Title
GT200600316A (es) Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
HN2008000311A (es) Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
NI201200072A (es) Métodos y composiciones para tratar cáncer
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
EA200900959A1 (ru) Ингибиторы мек
PA8660301A1 (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
ECSP088350A (es) Pirazolopirimidinas como inhibidores de protein quinasas
CR11107A (es) INDOLES SUSTITUIDOS EN LA POSICION 7 INHIBIDORES DE Mcl-1
CR10868A (es) Derivados de dihidropiridina utiles como inhibidores de la proteina quinasa
AR066042A1 (es) Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
GT200500260A (es) Amidas biciclicas como inhibidores de cinasa.
UY30477A1 (es) Derivados de [4,5']bipirimidinil-6,4´-diamina como inhibidores de cinasa de proteina
HN2006035237A (es) Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas
CR10566A (es) Compuestos heterociclicos adecuados para el tratamiento de enfermedades relacionadas con nivel elevado de lipidos
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA201070247A1 (ru) Ингибиторы протеасом
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
SV2007002813A (es) Compuestos para la modulacion de la actividad del c-fms y/o el c-kit y sus usos aplicables
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten